Cargando…
Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice
Background: Currently, there is no validated method for estimating antimicrobial consumption in the neonatal population, as it exists for adults using Defined Daily Doses (DDD). In neonatology, although there are different methods, each one with advantages and disadvantages, there is no unified crit...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044623/ https://www.ncbi.nlm.nih.gov/pubmed/36978469 http://dx.doi.org/10.3390/antibiotics12030602 |
_version_ | 1784913390287716352 |
---|---|
author | Villanueva-Bueno, Cristina Montecatine-Alonso, Elena Jiménez-Parrilla, Francisco González-López, María Manrique-Rodríguez, Silvia Moreno-Ramos, Francisco Cañete-Ramírez, Carme Dolz, Elisenda García-Robles, Ana Caro-Teller, José Manuel Moral-Pumarega, María Teresa Bergon-Sendin, Elena Gómez-Trevecedo Calvo, María Teresa Gallego-Fernández, Carmen del Vayo-Benito, Concepción Álvarez Mejías-Trueba, Marta Gil-Navarro, María Victoria |
author_facet | Villanueva-Bueno, Cristina Montecatine-Alonso, Elena Jiménez-Parrilla, Francisco González-López, María Manrique-Rodríguez, Silvia Moreno-Ramos, Francisco Cañete-Ramírez, Carme Dolz, Elisenda García-Robles, Ana Caro-Teller, José Manuel Moral-Pumarega, María Teresa Bergon-Sendin, Elena Gómez-Trevecedo Calvo, María Teresa Gallego-Fernández, Carmen del Vayo-Benito, Concepción Álvarez Mejías-Trueba, Marta Gil-Navarro, María Victoria |
author_sort | Villanueva-Bueno, Cristina |
collection | PubMed |
description | Background: Currently, there is no validated method for estimating antimicrobial consumption in the neonatal population, as it exists for adults using Defined Daily Doses (DDD). In neonatology, although there are different methods, each one with advantages and disadvantages, there is no unified criterion for use. The aim of this study is to validate the neonatal DDD designed as a new standardised form of antimicrobial consumption over this population. Methods: The validation of the neonatal DDD, Phase II of the research project, was carried out through a descriptive observational study. Periodic cut-offs were performed to collect antimicrobial prescriptions of neonates admitted to the neonatology and intensive care units of nine Spanish hospitals. The data collected included demographic variables (gestational age, postnatal age, weight and sex), antimicrobial dose, frequency and route of administration. The selection of the optimal DDD value takes into account power value, magnitude obtained from the differences in the DDD, statistical significance obtained by the Wilcoxon test and degree of agreement in the stipulated doses. Results: Set of 904 prescriptions were collected and finally 860 were analysed based on the established criteria. The antimicrobials were mostly prescribed in the intensive care unit (63.1%). 32 different antimicrobials were collected, and intravenous administration was the most commonly used route. Neonatal DDD were defined for 11 different antimicrobials. A potency > 80% was obtained in 7 antibiotics. The 57.1% of the selected DDD correspond to phase I and 21.4% from phase II. Conclusion: DDD validation has been achieved for the majority of intravenously administered antimicrobials used in clinical practice in the neonatal population. This will make it possible to have an indicator that will be used globally to estimate the consumption of antimicrobials in this population, thus confirming its usefulness and applicability. |
format | Online Article Text |
id | pubmed-10044623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100446232023-03-29 Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice Villanueva-Bueno, Cristina Montecatine-Alonso, Elena Jiménez-Parrilla, Francisco González-López, María Manrique-Rodríguez, Silvia Moreno-Ramos, Francisco Cañete-Ramírez, Carme Dolz, Elisenda García-Robles, Ana Caro-Teller, José Manuel Moral-Pumarega, María Teresa Bergon-Sendin, Elena Gómez-Trevecedo Calvo, María Teresa Gallego-Fernández, Carmen del Vayo-Benito, Concepción Álvarez Mejías-Trueba, Marta Gil-Navarro, María Victoria Antibiotics (Basel) Article Background: Currently, there is no validated method for estimating antimicrobial consumption in the neonatal population, as it exists for adults using Defined Daily Doses (DDD). In neonatology, although there are different methods, each one with advantages and disadvantages, there is no unified criterion for use. The aim of this study is to validate the neonatal DDD designed as a new standardised form of antimicrobial consumption over this population. Methods: The validation of the neonatal DDD, Phase II of the research project, was carried out through a descriptive observational study. Periodic cut-offs were performed to collect antimicrobial prescriptions of neonates admitted to the neonatology and intensive care units of nine Spanish hospitals. The data collected included demographic variables (gestational age, postnatal age, weight and sex), antimicrobial dose, frequency and route of administration. The selection of the optimal DDD value takes into account power value, magnitude obtained from the differences in the DDD, statistical significance obtained by the Wilcoxon test and degree of agreement in the stipulated doses. Results: Set of 904 prescriptions were collected and finally 860 were analysed based on the established criteria. The antimicrobials were mostly prescribed in the intensive care unit (63.1%). 32 different antimicrobials were collected, and intravenous administration was the most commonly used route. Neonatal DDD were defined for 11 different antimicrobials. A potency > 80% was obtained in 7 antibiotics. The 57.1% of the selected DDD correspond to phase I and 21.4% from phase II. Conclusion: DDD validation has been achieved for the majority of intravenously administered antimicrobials used in clinical practice in the neonatal population. This will make it possible to have an indicator that will be used globally to estimate the consumption of antimicrobials in this population, thus confirming its usefulness and applicability. MDPI 2023-03-17 /pmc/articles/PMC10044623/ /pubmed/36978469 http://dx.doi.org/10.3390/antibiotics12030602 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Villanueva-Bueno, Cristina Montecatine-Alonso, Elena Jiménez-Parrilla, Francisco González-López, María Manrique-Rodríguez, Silvia Moreno-Ramos, Francisco Cañete-Ramírez, Carme Dolz, Elisenda García-Robles, Ana Caro-Teller, José Manuel Moral-Pumarega, María Teresa Bergon-Sendin, Elena Gómez-Trevecedo Calvo, María Teresa Gallego-Fernández, Carmen del Vayo-Benito, Concepción Álvarez Mejías-Trueba, Marta Gil-Navarro, María Victoria Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title | Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title_full | Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title_fullStr | Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title_full_unstemmed | Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title_short | Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice |
title_sort | antimicrobial defined daily dose in neonatal population: validation in the clinical practice |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044623/ https://www.ncbi.nlm.nih.gov/pubmed/36978469 http://dx.doi.org/10.3390/antibiotics12030602 |
work_keys_str_mv | AT villanuevabuenocristina antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT montecatinealonsoelena antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT jimenezparrillafrancisco antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT gonzalezlopezmaria antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT manriquerodriguezsilvia antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT morenoramosfrancisco antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT caneteramirezcarme antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT dolzelisenda antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT garciaroblesana antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT carotellerjosemanuel antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT moralpumaregamariateresa antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT bergonsendinelena antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT gomeztrevecedocalvomariateresa antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT gallegofernandezcarmen antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT delvayobenitoconcepcionalvarez antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT mejiastruebamarta antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT gilnavarromariavictoria antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice AT antimicrobialdefineddailydoseinneonatalpopulationvalidationintheclinicalpractice |